Medicare Hemp Coverage Program Survives Federal Court Challenge

A federal judge dismissed the legal challenge to the Trump administration’s Medicare hemp initiative on May 22, 2026, clearing the first major courtroom test for a program that lets certain Medicare participants receive up to $500 in hemp-derived products annually. U.S. District Judge Trevor N. McFadden, sitting in Washington, D.C., threw out the suit brought by Smart Approaches to Marijuana and a coalition of drug-prevention organizations — but on procedural grounds, leaving the program’s underlying legality unresolved.

The ruling ends the groups’ bid for a court order blocking the Centers for Medicare & Medicaid Services program and disposes of their request for a preliminary injunction, which McFadden denied as moot following the dismissal.

The Standing Problem

Standing — the constitutional requirement that a plaintiff show a concrete, direct injury from the government action being challenged — proved fatal to every argument the challengers put forward.

The prohibitionist organizations, led by SAM and including groups such as the Drug Free America Foundation, argued that the hemp coverage initiative forced them to divert organizational resources away from other advocacy priorities. Judge McFadden found that none of them showed that the diversion actually interfered with their core work or prevented them from pursuing their stated missions. Objecting to a government program, the court held, is not a legal injury.

A cannabis-focused biopharmaceutical company, MMJ International Holdings, also joined the suit, claiming competitive harm from the new program. That argument failed as well. The company had no products on the Medicare beneficiary market and no clear timeline for entering it, making any claimed harm speculative.

The suit’s sole individual plaintiff, anti-marijuana attorney David Evans, claimed standing as a Medicare beneficiary who might someday receive a hemp product recommendation from his doctor. McFadden dismissed that theory too — even in that hypothetical scenario, Evans would face no concrete harm.

McFadden acknowledged the significance of hemp regulation as a policy matter and that the challengers hold strong views on it, but held that disapproving of the program does not constitute the kind of injury that opens federal courtroom doors. The dismissal order, signed May 22, 2026, found the entire suit lacking subject matter jurisdiction.

SAM rejected the outcome. “We fundamentally disagree with the court’s decision today,” said SAM president and CEO Kevin Sabet, adding that the group is reviewing options, including an appeal.

What the Program Actually Does

The initiative at the center of the case — the Substance Access Beneficiary Engagement Incentive — launched on April 1, 2026, through the CMS Innovation Center. The structure is worth understanding: CMS does not pay for the products. Instead, participating providers in select Innovation Center models can furnish eligible hemp-derived products at their own cost, up to $500 per beneficiary per year. The program’s underlying logic is that reducing symptoms may lower overall care costs and generate shared savings for participating organizations.

The program currently runs in two CMS models — the ACO REACH Model and the Enhancing Oncology Model — with a third, the Long-Term Enhanced ACO Design, opening to participants on January 1, 2027. Products must be orally administered, contain no more than 0.3 percent delta-9 THC, and include no more than 3 milligrams of total tetrahydrocannabinols per serving. Inhalable preparations are excluded.

The Trump administration enabled the initiative through a December 2025 executive order directing the attorney general to advance marijuana rescheduling and including provisions to expand access to hemp-derived CBD. The CMS press release announcing the April launch described the program as giving providers “another tool — with necessary safeguards — to support their patients’ needs.” FDA Commissioner Marty Makary reinforced that position the same day, issuing a non-enforcement memo indicating the agency would not move to block hemp CBD products furnished through qualifying CMS models.

SAM’s lawsuit had also raised substantive questions about whether CMS bypassed required rulemaking and public comment procedures before launching the program. Those questions were never reached. The standing dismissal leaves the program’s underlying legal validity untested by any court.

What Comes Next

SAM has indicated it may appeal the standing ruling to the D.C. Circuit Court of Appeals. The group has a separate lawsuit challenging the administration’s marijuana rescheduling effort, which is still pending in federal court.

The hemp regulation debate on Capitol Hill reflects how contested the policy space around hemp remains, even as the Medicare program holds for now. The initiative also faces a direct statutory pressure point: a provision in a recent federal agriculture spending law, set to take effect in November 2026, would significantly tighten federal THC limits for hemp products and could force CMS to revise its product eligibility standards mid-stream. CMS has acknowledged that contingency on its program page, noting it will update the program’s definitions if the legal limits on hemp-derived products change.

That pending shift — and where federal hemp policy lands after November 2026 — carries implications beyond Medicare. The dismissal removes a legal obstacle; it does not settle the policy ground beneath it.